BioCardia (NASDAQ:BCDA – Get Rating) and Vir Biotechnology (NASDAQ:VIR – Get Rating) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability and analyst recommendations.
Profitability
This table compares BioCardia and Vir Biotechnology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioCardia | -891.08% | -274.26% | -129.35% |
| Vir Biotechnology | N/A | -7.05% | -5.33% |
Risk & Volatility
BioCardia has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500. Comparatively, Vir Biotechnology has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500.
Insider and Institutional Ownership
Valuation & Earnings
This table compares BioCardia and Vir Biotechnology’s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioCardia | $1.35 million | 25.01 | -$11.91 million | ($0.64) | -2.61 |
| Vir Biotechnology | $397.25 million | 8.55 | $515.84 million | ($1.10) | -23.04 |
Vir Biotechnology has higher revenue and earnings than BioCardia. Vir Biotechnology is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent recommendations for BioCardia and Vir Biotechnology, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioCardia | 0 | 1 | 1 | 0 | 2.50 |
| Vir Biotechnology | 0 | 1 | 5 | 0 | 2.83 |
BioCardia presently has a consensus price target of $6.33, indicating a potential upside of 279.24%. Vir Biotechnology has a consensus price target of $49.75, indicating a potential upside of 96.33%. Given BioCardia’s higher possible upside, equities analysts clearly believe BioCardia is more favorable than Vir Biotechnology.
Summary
Vir Biotechnology beats BioCardia on 8 of the 14 factors compared between the two stocks.
About BioCardia
BioCardia, Inc. is a clinical-stage biotherapeutic company. It engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. The company was founded on January 12, 1994 and is headquartered in Sunnyvale, CA.
About Vir Biotechnology
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.
